NCT07519005

Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate whether extracorporeal perfusion using a gene-edited pig liver can significantly improve liver function and serve as a bridge-to-transplant therapy in patients with severe hepatic failure. It will also assess the survival and functionality of the xenogeneic liver and monitor the safety of the procedure. The main questions it aims to answer are: * Can extracorporeal perfusion with a gene-edited pig liver significantly improve liver function indicators (including biochemical, coagulation, and metabolic parameters) in patients with severe hepatic failure? * Is the gene-edited pig liver viable and functional during extracorporeal perfusion, as evidenced by bile secretion, adequate blood flow, and acceptable histopathological findings? * What adverse events occur in participants during and after extracorporeal xenogeneic liver perfusion? This is a single-arm study without a comparison group. Participants will: * Undergo screening assessments to confirm eligibility for severe hepatic failure diagnosis * Receive extracorporeal perfusion with a gene-edited pig liver for up to 14 days (or until transplantation/clinical improvement) * Receive intensive immunosuppressive therapy including tacrolimus, rituximab, ATG, mycophenolate mofetil, and other medications to prevent rejection Undergo hourly vital sign monitoring and daily blood tests (liver function, renal function, coagulation, inflammatory markers) during the perfusion period * Have daily abdominal ultrasounds and liver biopsies every other day to assess graft function and rejection

Detailed description

This is a single-center, prospective, open-label clinical trial designed to enroll one patient with severe hepatic failure to evaluate the safety and efficacy of extracorporeal perfusion using a gene-edited pig liver as a bridge-to-transplant therapy. Background and Rationale: Severe hepatic failure carries extremely high short-term mortality, and the scarcity of human donor livers limits treatment options. Xenotransplantation using genetically modified pigs represents a promising solution to organ shortage. This study builds on preclinical success in pig-to-non-human primate liver xenotransplantation and recent subclinical trials in brain-dead human recipients. By employing an extracorporeal (ex vivo) perfusion approach, the study minimizes surgical trauma to the patient while allowing assessment of xenogeneic liver function and compatibility. Study Population: The study will recruit one adult patient (age 18-70 years) with severe hepatic failure meeting the diagnostic criteria of the "Guidelines for Diagnosis and Treatment of Hepatic Failure (2024 Edition)." Eligible participants must have grade II or higher hepatic encephalopathy and a predicted poor prognosis with high short-term mortality (28-day mortality ≥15%). A third-party independent committee of three experts will assess natural mortality expectations to select appropriate candidates. Key exclusion criteria include immune dysfunction (e.g., HIV), prior allogeneic transplantation, or inability to tolerate surgical trauma. Intervention: The intervention involves connecting the patient to an extracorporeal perfusion circuit containing a liver from a six-gene-edited Bama miniature pig (provided by Sichuan Zhongke Aoge Biotechnology Co., Ltd.). The pig liver is procured using standard techniques with hypothermic perfusion (Schüssner's solution and hypertonic citrate-purine solution) and transported under strict cold storage conditions (1-6°C). Surgical Procedure: Under local anesthesia, vascular access is established via one internal jugular vein and one femoral vein. The patient is connected to the perfusion platform, and the preserved gene-edited pig liver is integrated into the extracorporeal circuit. Immunosuppression and Anti-inflammatory Regimen: Participants will receive a multi-drug immunosuppressive protocol including: Rituximab (375 mg/m²) pre-operatively Rabbit anti-human thymocyte immunoglobulin (ATG, 1-1.5 mg/kg/day for 2-3 days) Tacrolimus (target trough 15-25 ng/mL) Mycophenolate mofetil (1 g twice daily) Etanercept (anti-TNF-α, 25 mg twice weekly) Methylprednisolone (high-dose tapering regimen) Eculizumab (900 mg, 24 hours pre-perfusion) for complement inhibition Anticoagulation and Supportive Care: Heparin sodium will be administered to maintain APTT at 1.5-2.5 times normal and ACT at 200-300 seconds. Ganciclovir will be provided for cytomegalovirus prophylaxis. Standard supportive care for liver failure, including anti-infection therapy, hepatoprotective measures, and nutritional support, will be provided according to clinical guidelines. Primary Objectives: To observe changes in vital signs, physiological parameters, biochemical indicators, coagulation function, inflammatory responses, and immune-related markers in patients with severe hepatic failure following extracorporeal perfusion of gene-edited pig liver To evaluate whether the procedure can significantly improve liver function and serve as an effective bridge-to-transplant therapy Secondary Objectives: To evaluate the survival and functional viability of the pig liver through monitoring of bile secretion (volume and color), blood flow in portal vein/hepatic artery/hepatic vein, and histopathological examination of biopsy specimens every other day To explore perioperative management strategies and optimize the treatment protocol for extracorporeal liver perfusion To assess biosafety through daily monitoring of porcine endogenous retrovirus (PERV) and porcine cytomegalovirus to evaluate cross-species transmission risks Outcome Measures: Primary: Improvement in liver function parameters (bilirubin, INR, hepatic encephalopathy grade), coagulation function, and inflammatory markers; successful bridging to human liver transplantation or clinical recovery Secondary: Graft survival time, bile production quality, vascular patency on ultrasound, histological evidence of rejection (ISHLT grading), incidence of adverse events, and viral safety parameters Study Duration and Follow-up: The study period is from October 2025 to December 2026. Extracorporeal perfusion will continue until one of the following occurs: (1) successful bridging to allogeneic liver transplantation, (2) clinical recovery allowing discontinuation of support, (3) graft failure, (4) participant death, or (5) maximum duration of 14 days. If the initial graft fails, a second gene-edited pig liver may be used for continued perfusion. Safety Monitoring: Comprehensive safety monitoring includes hourly vital signs, daily laboratory assessments (CBC, liver/renal function, coagulation, tacrolimus levels), daily abdominal ultrasound, and rigorous adverse event documentation. An independent ethics committee oversees the study, and participants (or family members) may withdraw consent at any time prior to or during the procedure. Statistical Analysis: As a single-participant study, data will be analyzed descriptively. Continuous variables will be expressed as mean ± standard deviation, with changes from baseline documented longitudinally.

Conditions

• Hepatic Failure

Interventions

Type	Name	Description
BIOLOGICAL	Ex vivo perfusion of six-gene-edited porcine liver	Liver from a six-gene-edited Bama miniature pig (meeting designated pathogen-free standards) perfused extracorporeally using a specialized perfusion platform. The liver is procured using hypothermic preservation (Schüssner's solution and hypertonic citrate-purine solution), transported at 1-6°C, and connected to the patient via internal jugular and femoral venous access. The perfusion maintains physiological temperature and blood flow through the porcine liver while the patient's blood circulates through the graft.
DRUG	Multi-drug immunosuppressive therapy	Combination immunosuppression including rituximab, tacrolimus, mycophenolate mofetil, rabbit anti-thymocyte immunoglobulin (ATG), etanercept, methylprednisolone, and eculizumab administered according to a standardized protocol to prevent xenogeneic rejection.

Timeline

• Start date: 2026-01-31
• Primary completion: 2026-02-03
• Completion: 2026-12-31
• First posted: 2026-04-09
• Last updated: 2026-04-09

Locations

1 site across 1 country: China